Buyers of Zetia seek class recertification after 4th circ ruling
Wholesale buyers of MSD’s cholesterol treatment Zetia have asked a Virginia court to recertify their class status and move to trial following a recent fourth circuit ruling that reversed the court’s prior certification.
Pfizer targets Eucrisa generics in five Delaware suits
Pfizer subsidiary Anacor has filed five lawsuits targeting drug manufacturers looking to manufacture generic versions of its eczema treatment Eucrisa.
LSPN LIVE 2021: an ‘unmissable opportunity’
Over the past year, the life sciences sector has proved to be of vital importance in the fight against COVID-19. Now more than ever, it is imperative that IP professionals are best positioned to protect and leverage innovation in this fast-paced industry.
Cozen O’Connor adds ‘distinguished’ patent attorney in DC
Law firm Cozen O’Connor has hired patent counsellor Todd Buck to lead trade secret proceedings at its IP and business law practices in Washington DC.
PTAB affirms validity of three Medtronic patents in Axonics suit
The US Patent Trial and Appeal Board has confirmed the validity of three remaining Medtronic patents challenged by rival medical device manufacturer Axonics.
Elysium gets ChromaDex, Dartmouth vitamin patents invalidated
Dietary supplements company Elysium Health has convinced a Delaware court to invalidate two vitamin B3 patents belonging to rival ChromaDex and Dartmouth College.
Former FDA chief counsel joins Morrison & Foerster's DC office
Former Food and Drug Administration Chief Counsel Stacy Cline Amin has been hired as a partner at Morrison & Foerster’s life sciences and healthcare practice in Washington DC.
Zoetis sues rival over generic pet vomiting treatment
Veterinary drug maker Dechra’s generic of a drug that treats vomiting in dogs and cats, Cerenia, infringes a patent owned by its competitor Zoetis, a new lawsuit has alleged.
Lawmakers urge USPTO to curb IPR denials under Fintiv
Several US lawmakers have called upon the US Patent and Trademark Office to curb the increase in inter partes review denials to combat the “soaring cost” of prescription drugs.
Supernus hits Zydus with repeat suit over migraine drug
Supernus Pharmaceuticals has once again accused Indian generic drugmaker Zydus Cadila and its US unit of allegedly infringing 10 patents with its copycat of Trokendi XR (topiramate), a drug for migraines and seizures.
